Gulf Pharmaceutical Industries

JULPHAR ADX Health Care Shariah compliance: iStatus follows DFM's quarterly Shari'a compliant list (Q1 2026), screened under criteria approved by the DFM Fatwa & Shari'a Supervisory Board. Classification may change each quarter.
DFM Shari'a classification list ↗ ☆ Log in to watch

Price (AED)0.93 -2.43%Close · 30 Oct 2026

Market Cap1.07B

Enterprise Value1.03B iRoughly what it would cost to buy the whole company.How it is worked out: the value of its shares (market cap) + its debt − the cash it holds.Why it matters: two companies can have the same share value but very different debt and cash. Enterprise value shows the full picture, so you can compare them fairly.Versus market cap: 0.96×, so the company has more cash than debt.For this company: 1.07B + 273.00M debt + 9.10M minority interest − 320.80M cash = 1.03B (Q2 2026)Calculated · Q2 2026

P/E6.21

P/B1.13

Dividend Yield–

ROE18.14%

Volume: 1.32M1.19x 30-day average
Avg volume (30D): 1.11M

About the company

Gulf Pharmaceutical Industries (Julphar) was established in Ras Al Khaimah in 1980 and has been listed on the Abu Dhabi Securities Exchange since October 2002. It makes generic medicines for the retail pharmacy and hospital channels and is one of the larger insulin producers in the region, with manufacturing plants in the UAE. In 2025 it sold its UAE retail pharmacy chain and put its Oman operations and its Ethiopian subsidiary up for sale.

Industry: Health Care

www.julphar.net ↗

Prices from DFM: 1D and 5D from snapshots every 5 minutes during the session, longer ranges from daily closes. Hover to read a price, click and drag to measure the change between two points.

Year-end price history

Income Statement

Values in AED · click any row to chart the metric, click again to collapse

	Q3 '24	Q4 '24	Q1 '25	Q2 '25	Q3 '25	Q4 '25	Q1 '26	Q2 '26
Net Investment Income	–	800,000.00	2.5M	–	–	1.9M	2.5M	–
Revenue	236.9M	239.5M	281.9M	266.0M	249.7M	277.9M	273.4M	300.3M
Cost of Revenue	-141.1M	-146.1M	-173.4M	-153.7M	-147.5M	-165.0M	-153.7M	-158.8M
Gross Profit	95.8M	93.4M	108.5M	112.3M	102.2M	112.9M	119.7M	141.5M
Other Operating Income	-600,000.00	9.6M	1.5M	-700,000.00	2.0M	11.9M	1.9M	-1.3M
Selling, General & Admin	-89.9M	-89.7M	-97.1M	-101.2M	-95.2M	-93.4M	-89.9M	-108.4M
Operating Income	5.3M	13.3M	12.9M	10.4M	9.0M	31.4M	31.7M	31.8M
Finance Income	700,000.00	1.6M	2.5M	2.8M	1.3M	1.0M	900,000.00	1.5M
Finance Costs	-17.1M	-11.5M	-14.8M	-6.8M	-4.7M	-2.0M	-3.2M	-3.7M
Pre-Tax Income	-11.1M	4.2M	3.1M	6.4M	5.6M	32.3M	31.9M	29.6M
Income Tax Expense	1.8M	-3.6M	-1.6M	-2.3M	-300,000.00	700,000.00	-3.5M	-1.8M
Net Income	-5.1M	52.4M	125.8M	5.6M	9.1M	32.8M	35.1M	19.4M
Net Income (Owners of Parent)	-5.9M	51.9M	125.8M	5.5M	8.8M	32.1M	35.0M	21.1M
Non-Controlling Interests	800,000.00	500,000.00	–	100,000.00	300,000.00	700,000.00	100,000.00	-1.7M
EPS (AED)	-0.01	0.04	0.11	0.005	0.01	0.03	0.03	0.02

Balance Sheet

Values in AED · click any row to chart the metric, click again to collapse

	Q4 '23	Q1 '24	Q2 '24	Q3 '24	Q4 '24	Q1 '25	Q2 '25	Q3 '25	Q4 '25	Q1 '26	Q2 '26
Cash & Equivalents	204.8M	224.6M	200.4M	169.5M	147.3M	462.6M	343.7M	232.3M	245.4M	238.5M	320.8M
Trade & Other Receivables	578.1M	656.9M	718.5M	702.2M	860.6M	675.3M	635.8M	534.9M	530.0M	619.6M	733.1M
Other Assets & Prepayments	91.8M	60.1M	59.1M	36.0M	538.1M	73.6M	61.4M	307.2M	289.5M	294.3M	49.8M
Inventory	689.9M	674.9M	671.1M	601.9M	462.0M	405.9M	475.6M	393.4M	400.9M	398.3M	436.8M
Other Financial Assets	20.8M	20.8M	20.7M	20.8M	21.5M	21.5M	21.5M	21.5M	23.4M	23.4M	23.4M
Property, Plant & Equipment	573.6M	573.7M	564.2M	552.3M	255.6M	252.3M	250.3M	243.6M	243.3M	241.6M	242.8M
Right-of-Use Assets	135.5M	143.7M	154.8M	158.3M	58.4M	59.0M	62.9M	8.7M	11.2M	10.6M	9.3M
Intangible Assets	143.8M	144.2M	139.8M	136.3M	81.3M	81.2M	80.1M	34.1M	36.1M	35.8M	37.3M
Current Assets	1.6B	1.6B	1.6B	1.5B	2.0B	1.6B	1.5B	1.5B	1.5B	1.6B	1.6B
Total Assets	2.4B	2.5B	2.5B	2.4B	2.4B	2.0B	1.9B	1.8B	1.8B	1.9B	1.9B
Trade & Other Payables	427.1M	502.7M	529.0M	438.6M	397.5M	376.5M	414.6M	302.4M	352.9M	401.6M	467.5M
Income Tax Payable	7.7M	9.3M	9.7M	8.4M	5.2M	31.7M	15.0M	15.3M	17.2M	19.0M	20.7M
Deferred Tax Liabilities	8.0M	7.7M	7.6M	7.4M	8.3M	7.6M	7.2M	6.8M	2.9M	2.9M	2.7M
Loans & Borrowings	980.4M	964.5M	954.7M	921.2M	913.1M	529.9M	385.6M	263.8M	263.8M	263.8M	263.8M
Lease Liabilities	130.2M	139.1M	149.4M	153.4M	57.9M	58.8M	62.6M	7.9M	11.2M	10.5M	9.2M
End-of-Service Benefits	79.4M	82.4M	82.9M	84.9M	71.7M	74.7M	75.4M	66.1M	68.6M	67.0M	66.6M
Other Liabilities	9.7M	9.9M	7.0M	3.5M	171.9M	3.5M	3.8M	138.3M	103.4M	109.9M	6.8M
Current Liabilities	698.5M	783.6M	794.1M	673.3M	890.9M	529.1M	470.4M	458.1M	476.6M	549.2M	513.4M
Total Debt	1.1B	1.1B	1.1B	1.1B	971.0M	588.7M	448.2M	271.7M	275.0M	274.3M	273.0M
Total Liabilities	1.6B	1.7B	1.7B	1.6B	1.6B	1.1B	964.2M	800.6M	820.0M	874.7M	837.3M
Share Capital	1.2B	1.2B	1.2B	1.2B	1.2B	1.2B	1.2B	1.2B	1.2B	1.2B	1.2B
Reserves	-10.5M	-39.9M	-33.3M	-51.2M	-44.2M	-53.5M	-52.2M	-53.3M	-43.2M	-50.7M	-41.5M
Retained Earnings	-361.0M	-344.8M	-348.1M	-354.0M	-322.4M	-164.1M	-147.1M	-138.3M	-163.0M	-128.0M	-106.9M
Equity (Owners of Parent)	783.8M	770.6M	773.9M	750.1M	788.7M	937.7M	956.0M	963.7M	949.1M	976.6M	1.0B
Non-Controlling Interests	12.0M	12.7M	14.4M	9.8M	10.5M	11.0M	11.1M	11.4M	10.7M	10.8M	9.1M
Total Equity	795.8M	783.3M	788.3M	759.9M	799.2M	948.7M	967.1M	975.1M	959.8M	987.4M	1.0B

Cash Flow

Values in AED · click any row to chart the metric, click again to collapse

	Q3 '24	Q1 '25	Q2 '25	Q3 '25	Q4 '25	Q1 '26	Q2 '26
Operating Cash Flow	44.2M	-3.0M	51.3M	25.7M	46.9M	8.5M	-12.8M
Income Tax Paid	–	-1.9M	-900,000.00	-400,000.00	-200,000.00	-1.7M	-1.8M
Investing Cash Flow	-14.7M	746.4M	-24.3M	-18.8M	-23.4M	-5.5M	-14.3M
Capital Expenditure	-9.9M	-8.9M	-8.1M	-15.8M	-13.2M	-8.2M	-11.0M
Financing Cash Flow	-47.1M	-405.9M	-149.1M	-126.2M	-5.6M	-8.8M	-4.3M
Proceeds from Borrowings	200.5M	–	297.5M	219.3M	342.5M	–	–
Repayment of Borrowings	-234.0M	-383.2M	-441.8M	-341.1M	-342.5M	–	–
Lease Payments	-17.1M	-4.6M	-3.9M	-6.6M	-5.5M	-5.6M	-700,000.00
Finance Costs Paid	-12.2M	-18.1M	-10.8M	-4.0M	–	-3.2M	-3.6M
Free Cash Flow	34.3M	-11.9M	43.2M	9.9M	33.7M	300,000.00	-23.8M

Market Information

2026-08-13 Q2 2026 Financial Results PDF ↓
2026-05-14 Q1 2026 Financial Results PDF ↓
2026-03-27 FY 2025 Financial Results PDF ↓
2025-11-13 Q3 2025 Financial Results PDF ↓
2025-08-13 Q2 2025 Financial Results PDF ↓
2025-05-14 Q1 2025 Financial Results PDF ↓
2025-03-18 FY 2024 Financial Results PDF ↓
2024-11-14 Q3 2024 Financial Results PDF ↓
2024-03-15 FY 2023 Financial Results PDF ↓

Gulf Pharmaceutical Industries

About the company

Year-end price history

Shariah screening

Dividend calculator

Dividend history

Announcements

Income Statement

Balance Sheet

Cash Flow

Revenue

Gross Profit

Operating Income

EBITDA

Net Income

EPS (AED)

Shares Outstanding

Total Assets

Cash & Equivalents

Long Term Debt

Total Liabilities

Total Equity

Profitability Margins

Gross Margin

Operating Margin

EBITDA Margin

Pre-Tax Margin

Net Margin

P/E

P/S Ratio

P/B

Price / FCF

Net Worth (Market Cap)

Current Ratio

Quick Ratio

Debt / Equity

ROE

ROA

ROI

Return on Tangible Equity

Dividend Yield

Employee Count

Market Information